Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
---|
05/08/2003 | WO2003037349A1 Type 4 phosphodiesterase inhibitors and uses thereof |
05/08/2003 | WO2003037339A1 Interferon $g(g) production promoter |
05/08/2003 | WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
05/08/2003 | WO2003037335A1 5-heteroatom-substituted pyrazoles |
05/08/2003 | WO2003037332A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
05/08/2003 | WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors |
05/08/2003 | WO2003037327A1 N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors |
05/08/2003 | WO2003037300A1 Gastric raft composition |
05/08/2003 | WO2003037299A1 Novel formulation |
05/08/2003 | WO2003037268A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
05/08/2003 | WO2003037266A2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
05/08/2003 | WO2003023404A8 A method of diagnosis and treatment and agents useful for same |
05/08/2003 | WO2003012105A3 Vegf isoform |
05/08/2003 | WO2003000027A3 Blocking peptide for inflammatory cell secretion |
05/08/2003 | WO2002102305B1 Adjuvant composition for mucosal and injection delivered vaccines |
05/08/2003 | WO2002090524A3 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof |
05/08/2003 | WO2002085414A3 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
05/08/2003 | WO2002081499A3 Somatostatin agonists |
05/08/2003 | WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
05/08/2003 | WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate |
05/08/2003 | WO2002026946A3 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
05/08/2003 | WO2002026223A3 Catecholamine pharmaceutical compositions and methods |
05/08/2003 | WO2002024715A3 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
05/08/2003 | WO2002010216A3 Proteins and nucleic acids encoding same |
05/08/2003 | US20030088111 Protected forms of pharmacologically active agents and uses therefor |
05/08/2003 | US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
05/08/2003 | US20030087957 Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same |
05/08/2003 | US20030087950 New alpha-amino acid sulphonyl compounds |
05/08/2003 | US20030087930 Process for preparing 2-(4-chlorobenzolamino)-3[ (1h)-quinolinon-4-yl] propionic acid |
05/08/2003 | US20030087926 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
05/08/2003 | US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
05/08/2003 | US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines |
05/08/2003 | US20030087916 Pyrimidin-4-one compounds |
05/08/2003 | US20030087912 Aryl oxime-piperazines useful as CCR5 antagonists |
05/08/2003 | US20030087910 E.g., O-(2-quinolinylmethyl)-N-quinaldoyl-D,L-tyrosine |
05/08/2003 | US20030087904 Xanthine derivatives, such as 3-isobutyl-8-pyrrolidinylxanthine; treating asthma, diarrhea, etc. |
05/08/2003 | US20030087903 Mevinolin derivatives |
05/08/2003 | US20030087902 Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents |
05/08/2003 | US20030087898 Opioid receptor antagonists; treating irritable bowel syndrome, drug addiction or dependency, depression, and eating disorders. |
05/08/2003 | US20030087890 Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide |
05/08/2003 | US20030087882 Antiinflammatory agents |
05/08/2003 | US20030087875 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
05/08/2003 | US20030087839 Combined preparations comprising morpholine anthracyclines and anticancer agent |
05/08/2003 | US20030087831 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient |
05/08/2003 | US20030087828 Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof |
05/08/2003 | US20030087816 Anticancer, antitumor agents; genetic engineering |
05/08/2003 | US20030087803 Insertion drugs into cells, tissue; therapy for brain disorders, central nervous system disorders |
05/08/2003 | US20030087384 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment fibroblast growth factor receptor defects |
05/08/2003 | US20030087307 Compound for use in the prevention and treatment of respiratory and nervous system disorders |
05/08/2003 | US20030087249 93870, a human G-protein coupled receptor and uses therefor |
05/08/2003 | US20030086980 Method for the suppression of visceral pain by regulating T type calcium channel |
05/08/2003 | US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated |
05/08/2003 | US20030086968 Administering to human an amount of (-) pantoprazole, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer to alleviate or palliate ulcers |
05/08/2003 | US20030086965 Combination chemotherapy |
05/08/2003 | US20030086919 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor |
05/08/2003 | US20030086914 Method and device for inducing biological processes by micro-organs |
05/08/2003 | US20030086901 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
05/08/2003 | CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders |
05/08/2003 | CA2466152A1 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
05/08/2003 | CA2465497A1 Bridged bicyclic amino acid-derived (1,4) benzodiazepine vasopressin receptor antagonists |
05/08/2003 | CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
05/08/2003 | CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
05/08/2003 | CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
05/08/2003 | CA2465306A1 Substituted 1h-quinolin-2-one compounds |
05/08/2003 | CA2465236A1 Substituted indoles, method for production and use thereof for the inhibition of pain |
05/08/2003 | CA2464997A1 Silicon compounds |
05/08/2003 | CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles |
05/08/2003 | CA2464727A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
05/08/2003 | CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
05/08/2003 | CA2464342A1 Therapeutic isoquinoline compounds |
05/08/2003 | CA2464191A1 Substituted benzo[b]azepin-2-one compounds |
05/08/2003 | CA2463770A1 Compounds useful as reversible inhibitors of cysteine proteases |
05/08/2003 | CA2463441A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
05/08/2003 | CA2462660A1 Nucleic acid-associated proteins |
05/08/2003 | CA2462525A1 Type 4 phosphodiesterase inhibitors and uses thereof |
05/08/2003 | CA2462206A1 Substituted thioacetamides |
05/08/2003 | CA2426785A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
05/07/2003 | EP1308509A1 Novel physiologically active peptide and use thereof |
05/07/2003 | EP1308462A1 Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof |
05/07/2003 | EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles |
05/07/2003 | EP1308445A1 5-heteroatom-substituted pyrazoles |
05/07/2003 | EP1308441A1 2-aminopyridine compounds and use thereof as drugs |
05/07/2003 | EP1308440A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient |
05/07/2003 | EP1308439A1 Proline derivatives and use thereof as drugs |
05/07/2003 | EP1308161A1 5-N-heterocyclyl-1-(4-sulfonyl-phenyl)-1H-pyrazole derivatives with cyclooxygenase 2 (COX-2) inhibiting activity for the treatment of inflammatory diseases |
05/07/2003 | EP1308158A1 Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors |
05/07/2003 | EP1307593A1 Screening of a novel hepatic syndrome and its uses |
05/07/2003 | EP1307554A2 C3b/c4b complement receptor-like molecules and uses thereof |
05/07/2003 | EP1307486A2 Somatostatin analogues |
05/07/2003 | EP1307461A2 Substituted pyrrole compounds and their use as spla2 inhibitors |
05/07/2003 | EP1307458A1 Pyrrolotriazolopyrimidinone derivatives |
05/07/2003 | EP1307455A2 Inhibitors of alpha-l beta-2 mediated cell adhesion |
05/07/2003 | EP1307453A2 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
05/07/2003 | EP1307449A1 1,4-dihydropyridines as bradykinin antagonists |
05/07/2003 | EP1307432A1 Cyclic oxyguanidine protease inhibitors |
05/07/2003 | EP1307430A1 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
05/07/2003 | EP1307425A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
05/07/2003 | EP1307264A2 New pharmaceutical composition |
05/07/2003 | EP1307262A1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
05/07/2003 | EP1307219A2 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |